o Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. It is associated with a 5-fold risk of stroke, a 3-fold incidence of congestive heart failure, a 3-fold risk of ventricular fibrillation and higher mortality 1,2 .
Introduction and objectives
o Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. It is associated with a 5-fold risk of stroke, a 3-fold incidence of congestive heart failure, a 3-fold risk of ventricular fibrillation and higher mortality 1, 2 .
o Pharmacological cardioversion or direct current cardioversion (DCC) are done to restore a normal sinus rhythm.
o There is evidence that a shorter time to cardioversion significantly reduces the risk of thromboembolic complications 3 .
o Vernakalant is an antiarrhythmic drug indicated to rapidly convert recent onset AF to sinus rhythm in adults, or in case of post-cardiac surgery AF ≤ 3 days 4 . (Table 2) .
Introduction
o Given the relative frequencies of amiodarone (55%) and DCC (45%) to treat AF in Belgian ED, the weighted average management cost was € 1,470 (+€117/treatment vs vernakalant). 
Objectives
We aimed at estimating and comparing the total management costs, from the Belgian healthcare payer perspective (INAMI/ RIZIV + co-pay), of patients admitted to the emergency department (ED) with recent (<48 hours) AF treated with: DCC, amiodarone IV and vernakalant IV.
Data inputs, assumptions and sources
o The cardioversion success rates were based on the published observational studies RHYTHM-AF (DCC 90%, amiodarone 68%) 5 and Malmö study (vernakalant 70%) 6 .
o In case of successful conversion:
• the patient was released from the ED to home on the same day, with the following probabilities: DCC 50% 5 , amiodarone 25% 5 , vernakalant 100% 6 • Patients not discharged were admitted to the hospital for a median of 1 day (DCC) or 2 days (amiodarone), based on the distributions of the length of stay in RHYTHM-AF.
o In case of failed cardioversion: all patients were admitted to hospital (cf. costs in Table 1 ).
One-way sensitivity analysis
o A break-even situation (same costs for vernakalant and usual care) is reached when 70% of successfully treated vernakalant patients avoid the hospitalization (Figure 2 ).
Two-way sensitivity analyses
o Savings can also be generated with discharge rates below 70% for successfully treated patients, if at least 30% of the patients are discharged during the same day after a failed cardioversion with vernakalant.
o Other combinations can lead to a break-even situation:
• 100% of the patients are discharged to home with DCC and <15% with amiodarone • 40% are discharged after DCC and <45% with amiodarone.
Probabilistic sensitivity analysis
o Vernakalant was cost saving in 60% of the 1,000 simulations vs. the average current management of AF (32% vs. DCC and 68% vs. amiodarone; probabilities variations ±10% around base case).
